GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (NAS:ARDX) » Definitions » Price-to-Tangible-Book
中文

Ardelyx (Ardelyx) Price-to-Tangible-Book

: 9.05 (As of Today)
View and export this data going back to 2014. Start your Free Trial

As of today (2024-04-24), Ardelyx's share price is $6.495. Ardelyx's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.72. Hence, Ardelyx's Price to Tangible Book Ratio of today is 9.05.

The historical rank and industry rank for Ardelyx's Price-to-Tangible-Book or its related term are showing as below:

ARDX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.97   Med: 3.95   Max: 9.14
Current: 9.02

During the past 12 years, Ardelyx's highest Price to Tangible Book Ratio was 9.14. The lowest was 0.97. And the median was 3.95.

ARDX's Price-to-Tangible-Book is ranked worse than
86.95% of 1218 companies
in the Biotechnology industry
Industry Median: 2.69 vs ARDX: 9.02

A closely related ratio is called PB Ratio. As of today, Ardelyx's share price is $6.495. Ardelyx's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.72. Hence, Ardelyx's P/B Ratio of today is 9.05.


Ardelyx Price-to-Tangible-Book Historical Data

The historical data trend for Ardelyx's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.57 4.80 1.73 5.76 8.64

Ardelyx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.76 8.19 6.00 4.96 8.64

Competitive Comparison

For the Biotechnology subindustry, Ardelyx's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ardelyx Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, Ardelyx's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Ardelyx's Price-to-Tangible-Book falls into.



Ardelyx Price-to-Tangible-Book Calculation

Ardelyx's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=6.495/0.718
=9.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Ardelyx Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Ardelyx's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Ardelyx (Ardelyx) Business Description

Traded in Other Exchanges
Address
400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Executives
David P. Rosenbaum officer: Chief Development Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Justin A Renz officer: Chief Financial Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Elizabeth A Grammer officer: See Remarks 78TH FOURTH AVENUE, WALTHAM MA 02451
Robert Blanks officer: See Remarks C/O ARDELYX, 34175 ARDENWOOD BLVD., FREMONT CA 94555
Laura A Williams officer: Chief Medical Officer 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Robert Ora Felsch officer: See Remarks C/O ARDELYX, INC., 34175 ARDENWOOD BLVD., FREMONT CA 94555
Michael Raab director, officer: President & CEO 1119 ST PAUL STREET, BALTIMORE MD 21202
Susan Rodriguez officer: Chief Commercial Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Forest Baskett 10 percent owner
Scott D Sandell 10 percent owner
Jeffrey W Jacobs officer: VP, Chemistry C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Keith Santorelli officer: See Remarks C/O ARDELYX, INC. 34175 ARDENWOOD BLVD, FREMONT CA 94555
Onaiza Cadoret-manier director 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010